

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
21 July 2005 (21.07.2005)

PCT

(10) International Publication Number
WO 2005/066348 A2

(51) International Patent Classification⁷: **C12N 15/62**,
A61K 47/48, C07K 14/54, 16/30, A61P 35/00

(21) International Application Number:
PCT/GB2005/000007

(22) International Filing Date: 5 January 2005 (05.01.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/534,307 5 January 2004 (05.01.2004) US

(71) Applicants (*for all designated States except US*): **EMD LEXIGEN RESEARCH CENTER CORP.** [US/US]; 45a Middlesex Turnpike, Bedford Campus, Billerica, MA 01821 (US). **ANTISOMA PLC** [GB/GB]; West Africa House, Hanger Lane, Ealing, London W5 3QR (GB).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **GILLIES, Stephen** [US/US]; 47 Swanson Lane, Carlisle, MA 01741 (US). **LO, Kin-Ming** [US/US]; 6 Carol Lane, Lexington, MA 02420 (US). **LAN, Yan** [CN/US]; 21 Newton Street, Belmont, MA 02178 (US). **VERMA, Rakesh** [GB/GB]; 15 Laurel Court, Vicars Bridge Close, Alperton, London HA0 1XY (GB).

(74) Agent: **THOMAS, Philip**; Eric Potter Clarkson, Park View House, 58 The Ropewalk, Nottingham NG1 5DD (GB).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,

[Continued on next page]

(54) Title: COMPOUNDS FOR TARGETING



(57) Abstract: The invention provides a compound comprising a target specific portion and an effector portion wherein the target specific portion comprises or consists of a monoclonal antibody having specificity for oncofoetal fibronectin, or a fragment or variant thereof which retains the antigen binding specificity of the parent monoclonal antibody and the effector portion comprises or consists of interleukin-12, or a functional fragment or variant thereof, characterised in the monoclonal antibody having specificity for oncofoetal fibronectin binds to a region of oncofoetal fibronectin other than the ED-B region. The invention further provides nucleic acids encoding the compounds of the invention, and the use of such compounds in medicine, e.g. in the treatment of cancer.

WO 2005/066348 A2



PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,

SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.